Andrew M Hill

List of Publications by Year
in descending order

112 papers	3,943 citations	117453 34 h-index	149479 56 g-index
120 all docs	120 docs citations	120 times ranked	5913 citing authors

#	Article	IF	Citations
1	Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). Journal of Antimicrobial Chemotherapy, 2022, 77, 758-766.	1.3	15
2	Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. Open Forum Infectious Diseases, 2022, 9, ofab645.	0.4	34
3	Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 456-462.	0.3	112
4	Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud. Journal of Antimicrobial Chemotherapy, 2022, 77, 1413-1416.	1.3	10
5	Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1301-1304.	0.6	17
6	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. Stroke, 2022, 53, 1759-1763.	1.0	36
7	Editorial: does<scp>TAF</scp>have a better or worse safety profile than<scp>TDF</scp>, to treat hepatitis B?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1042-1043.	1.9	1
8	Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19. Open Forum Infectious Diseases, 2022, 9, .	0.4	11
9	Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofab581.	0.4	16
10	Current prices versus minimum costs of production for CFTR modulators. Journal of Cystic Fibrosis, 2022, 21, 866-872.	0.3	21
11	Molnupiravirâ€™s authorisation should be re-evaluated after the Panoramic trial is reported. BMJ, The, 2022, 377, o973.	3.0	2
12	Dose prediction for repurposing nitazoxanide in SARSâ€CoVâ€2 treatment or chemoprophylaxis. British Journal of Clinical Pharmacology, 2021, 87, 2078-2088.	1.1	46
13	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. Journal of Antimicrobial Chemotherapy, 2021, 76, 286-291.	1.3	29
14	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 753-757.	1.3	50
15	Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?. Drugs, 2021, 81, 299-315.	4.9	34
16	Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. Wellcome Open Research, 2021, 6, 1.	0.9	10
17	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. Aids, 2021, 35, 205-211.	1.0	11
18	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Current Opinion in Infectious Diseases, 2021, 34, 16-24.	1.3	20

#	Article	IF	Citations
19	Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. Clinical Infectious Diseases, 2021, 73, e1008-e1010.	2.9	15
20	Atrial Fibrillation and Stroke. Cardiac Electrophysiology Clinics, 2021, 13, 243-255.	0.7	23
21	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	0.7	48
22	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication. Current Opinion in HIV and AIDS, 2021, 16, 106-114.	1.5	7
23	Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. Aids, 2021, 35, 1657-1665.	1.0	40
24	Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. Aids, 2021, 35, 1423-1432.	1.0	31
25	The Joint United Nations Programme on HIV/AIDS 95â€“95â€“95 targets: worldwide clinical and cost benefits of generic manufacture. Aids, 2021, 35, S197-S203.	1.0	54
26	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. Aids, 2021, 35, S117-S125.	1.0	12
27	Impact of long-acting therapies on the global HIV epidemic. Aids, 2021, 35, S137-S143.	1.0	16
28	Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. Aids, 2021, 35, 759-767.	1.0	7
29	Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. Aids, 2021, 35, S127-S135.	1.0	21
30	What we have learned from antiretroviral treatment optimization efforts over the last 5 years?. Aids, 2021, 35, S113-S115.	1.0	2
31	Is tenofovir disoproxil fumarate associated with weight loss?. Aids, 2021, 35, S189-S195.	1.0	25
32	Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.. Iranian Journal of Pharmaceutical Research, 2021, 20, 278-288.	0.3	1
33	SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases, 2020, 70, 2206-2212.	2.9	19
34	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. Aids, 2020, 34, 321-324.	1.0	4
35	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV,the, 2020, 7, e666-e676.	2.1	145
36	Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries. Journal of Virus Eradication, 2020, 6, 100001.	0.3	23

#	Article	IF	Citations
37	Weighing considerations with newer antiretrovirals. Lancet HIV,the, 2020, 7, e374-e375.	2.1	5
38	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 3373-3378.	1.3	78
39	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal of Antimicrobial Chemotherapy, 2020, 75, 3366-3372.	1.3	81
40	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 3379-3385.	1.3	95
41	Prioritization of Antiâ€SARSâ€Covâ€2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2020, 108, 775-790.	2.3	118
42	How a US-UK trade agreement could affect NHS drug prices. BMJ, The, 2020, 369, m1332.	3.0	3
43	Avoiding Stroke: A Continuous Monitoring Challenge. Cerebrovascular Diseases, 2020, 49, 121-123.	0.8	1
44	Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of Virus Eradication, 2020, 6, 52-60.	0.3	38
45	Minimum costs to manufacture new treatments for COVID-19. Journal of Virus Eradication, 2020, 6, 61-69.	0.3	63
46	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of Virus Eradication, 2020, 6, 70-73.	0.3	4
47	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virusâ€“Infected Individuals. Clinical Infectious Diseases, 2019, 68, 446-452.	2.9	21
48	Global access of rifabutin for the treatment of tuberculosis â€“ why should we prioritize this?. Journal of the International AIDS Society, 2019, 22, e25333.	1.2	19
49	Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV,the, 2019, 6, e428-e437.	2.1	14
50	Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: AÂrandomised trial (DolPHIN-1 study). PLoS Medicine, 2019, 16, e1002895.	3.9	58
51	Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 224-233.	0.9	11
52	Are new antiretroviral treatments increasing the risks of clinical obesity?. Journal of Virus Eradication, 2019, 5, 41-43.	0.3	35
53	Estimated costs of production and potential prices for the WHO Essential Medicines List. BMJ Global Health, 2018, 3, e000571.	2.0	55
54	Is hepatitis C virus elimination possible among people living with <scp>HIV</scp> and what will it take to achieve it?. Journal of the International AIDS Society, 2018, 21, e25062.	1.2	39

#	Article	IF	Citations
55	Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals. Current Opinion in HIV and AIDS, 2018, 13, 102-111.	1.5	48
56	The unexpected success of NRTIs in second-line treatment. Lancet Infectious Diseases, The, 2018, 18, 3-5.	4.6	19
57	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	1.3	102
58	Production costs and potential prices for biosimilars of human insulin and insulin analogues. BMJ Global Health, 2018, 3, e000850.	2.0	42
59	Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Medicine, 2018, 16, 175.	2.3	51
60	The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries. Aids, 2018, 32, 1551-1561.	1.0	96
61	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. Journal of Virus Eradication, 2018, 4, 72-79.	0.3	44
62	Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals. Journal of Virus Eradication, 2018, 4, 128-131.	0.3	9
63	Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. Journal of Virus Eradication, 2018, 4, 66-71.	0.3	20
64	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. Journal of Virus Eradication, 2018, 4, 215-224.	0.3	34
65	Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries. Journal of Virus Eradication, 2018, 4, 230-237.	0.3	4
66	Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open, 2017, 7, e011965.	0.8	30
67	Rapidly declining HIV infection in MSM in central London. Lancet HIV,the, 2017, 4, e482-e483.	2.1	86
68	Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review. Open Forum Infectious Diseases, 2017, 4, ofw252.	0.4	18
69	Highlights from the 24 Conference on Retroviruses and Opportunistic Infections: 13-16 February 2017, Seattle, Washington, USA. Journal of Virus Eradication, 2017, 3, 101-108.	0.3	1
70	The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. Journal of Virus Eradication, 2017, 3, 117-123.	0.3	63
71	High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C. Journal of Virus Eradication, 2017, 3, 200-203.	0.3	16
72	InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. Journal of Virus Eradication, 2017, 3, 218-222.	0.3	10

#	Article	IF	Citations
73	Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. AIDS Reviews, 2017, 19, 16-23.	0.5	7
74	Choice of antiretroviral drugs for continued treatment scaleâ€up in a public health approach: what more do we need to know?. Journal of the International AIDS Society, 2016, 19, 20504.	1.2	33
75	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open, 2016, 6, e009586.	0.8	49
76	Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2016, 62, 683-694.	2.9	262
77	Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. Journal of Virus Eradication, 2016, 2, 28-31.	0.3	39
78	Switch to etravirine for <scp>HIV</scp>â€positive patients receiving statin treatment: a prospective study. European Journal of Clinical Investigation, 2015, 45, 720-730.	1.7	5
79	CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and metaâ€analysis. Journal of the International AIDS Society, 2015, 18, 20061.	1.2	23
80	Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clinical Infectious Diseases, 2015, 61, 730-740.	2.9	229
81	Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. International Journal of Drug Policy, 2015, 26, 1088-1093.	1.6	27
82	Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up. Journal of Antimicrobial Chemotherapy, 2015, 70, 627-630.	1.3	10
83	When can HIV clinical trials detect treatment effects on drug resistance?. International Journal of STD and AIDS, 2015, 26, 268-278.	0.5	1
84	The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infectious Diseases, The, 2015, 15, 241-247.	4.6	115
85	Editorial Commentary: Comparative Efficacy of Lamivudine and Emtricitabine: Comparing the Results of Randomized Trials and Cohorts. Clinical Infectious Diseases, 2015, 60, 154-156.	2.9	10
86	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. Journal of Virus Eradication, 2015, 1, 103-10.	0.3	16
87	Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break points. Journal of the International AIDS Society, 2014, 17, 19507.	1.2	52
88	Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. Journal of the International AIDS Society, 2014, 17, 19583.	1.2	14
89	Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. Journal of the International AIDS Society, 2014, 17, 19497.	1.2	29
90	Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naÃ¯ve and experienced HIV-infected patients: a medium-term follow-up. Journal of the International AIDS Society, 2014, 17, 19822.	1.2	2

#	Article	IF	Citations
91	Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa. Journal of the International AIDS Society, 2014, 17, 19604.	1.2	6
92	Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. Journal of the International AIDS Society, 2014, 17, 19788.	1.2	16
93	Does pregnancy affect the pharmacokinetics of efavirenz?. Aids, 2014, 28, 1542-1543.	1.0	7
94	Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. Clinical Infectious Diseases, 2014, 58, 928-936.	2.9	197
95	Hepatitis C can be cured globally, but at what cost?. Science, 2014, 345, 141-142.	6.0	60
96	Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapyâ€"Implications for Sustained Efficacy of ART in Resource-Limited Settings. Journal of Infectious Diseases, 2013, 207, S78-S84.	1.9	29
97	Optimizing HIV treatment. Current Opinion in HIV and AIDS, 2013, 8, 34-40.	1.5	11
98	The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Reviews, 2011, 13, 41-8.	0.5	9
99	Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts. Pharmacoeconomics, 2010, 28, 169-181.	1.7	2
100	d4T: keep it or abandon it?. Asian Biomedicine, 2010, 4, 541-546.	0.2	2
101	The ABC of HIV Clinical Trials. Pharmaceutical Medicine, 2009, 23, 201-211.	1.0	0
102	Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels. HIV Clinical Trials, 2009, 10, 1-12.	2.0	33
103	Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Reviews, 2009, 11, 30-8.	0.5	58
104	Designing and interpreting HIV noninferiority trials in naive and experienced patients. Aids, 2008, 22, 913-921.	1.0	38
105	Modelling-Based Prediction of Clinical Benefits from Etravirine in the TMC125-C223 Trial. HIV Clinical Trials, 2007, 8, 68-76.	2.0	2
106	Balancing effectiveness and access to HIV treatment in the developing world. Aids, 2007, 21, 361-363.	1.0	7
107	Analysis of Costs by CD4 Count Category for the Darunavir/r 600/100 mg bid and Control Protease Inhibitor Arms of the POWER 1 and 2 Trials. HIV Clinical Trials, 2007, 8, 303-310.	2.0	7
108	Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?. Aids, 2007, 21, 1651-1653.	1.0	10

#	Article	IF	Citations
109	Predicting HIV care costs using CD4 counts from clinical trials. American Journal of Managed Care, 2007, 13, 524-8.	0.8	6
110	A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial. Antiviral Therapy, 2006, 11, 761-770.	0.6	31
111	Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints. Antiviral Therapy, 2005, 10, 367-74.	0.6	4
112	Discordant Conclusions from HIV Clinical Trials â€" An Evaluation of Efficacy Endpoints. Antiviral Therapy, 2005, 10, 367-374.	0.6	10